Personalizezed Hemodynamic Optimization Using Stroke Volume, Pulse Pressure Variation, and Continuous Cardiac Index in Major Liver Surgery: A Randomized Controlled Trial
Francisco Javier Redondo Calvo, Víctor Baladrón González, David Padilla Valverde, Jorge Redondo Sánchez, Pedro Juan Villarejo Campos, Omar Montenegro Herrera, Patricia Faba Martín, Rubén Villazala González, Raquel Bodoque Villar, Juan Fernando Padin, José Ramón Muñoz-Rodríguez

TL;DR
This study shows that personalized hemodynamic therapy during major liver surgery reduces blood loss and transfusion needs compared to standard care.
Contribution
The novel use of stroke volume, pulse pressure variation, and continuous cardiac index to guide personalized fluid therapy in liver surgery.
Findings
Patients in the GDHT group had significantly less blood loss compared to the control group.
Fewer patients in the GDHT group required intraoperative transfusion.
Total fluid volume administered was significantly lower in the GDHT group.
Abstract
Background/Objectives: The aim of this study was to evaluate fluid administration and intraoperative bleeding of patients who had major hepatic resection. We used artery pulse contour analysis monitor (ProAQT™) and personalized hemodynamic target-guided therapy, in which the administration of fluid, inotropes and vasopressors is guided by stroke volume, pulse pressure variation (SVV, PPV) and continuous cardiac index (CI). Methods: This trial was a prospective, randomized, parallel-group in adults scheduled for major hepatic resection. Participants were randomly assigned in equal numbers to one of two groups: (1) a control group receiving conventional perioperative care, and (2) an intervention group managed with goal-directed hemodynamic therapy guided by radial artery pulse contour analysis. Results: 45 patients were randomized to the GDHT (n = 16) and control group (n = 19). Blood…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHemodynamic Monitoring and Therapy · Cardiac, Anesthesia and Surgical Outcomes · Blood Pressure and Hypertension Studies
1. Introduction
Intraoperative hemorrhage remains one of the leading contributors to morbidity and mortality during liver surgery [1]. To mitigate bleeding, surgical strategies often focus on limiting hepatic blood flow. Among these, the Pringle maneuver (PM), which involves clamping the portal triad, is the most commonly employed technique. However, its clinical value has been debated due to potential risks such as hemodynamic instability and ischemia–reperfusion injury [2].
A widely adopted approach to minimize blood loss during hepatic resections is maintaining a low central venous pressure (CVP), typically below 5–6 cm H_2_O, through fluid restriction [3]. Once the resection is complete, fluid resuscitation is generally used to restore euvolemia.
Traditional cardiac filling pressures, including CVP and pulmonary artery occlusion pressure (PAOP), have proven unreliable in predicting fluid responsiveness [4]. CVP readings can be influenced by multiple intraoperative factors such as mechanical ventilation, PM application, changes in peripheral resistance, and elevated intra-abdominal pressure [5]. Moreover, some studies have reported no significant correlation between low CVP and reduced bleeding [6].
Currently, many surgical teams favor restrictive fluid management protocols during liver resections, opting not to rely on cardiac filling pressures for guidance [7].
Dynamic preload indicators such as stroke volume variation (SVV) and pulse pressure variation (PPV) are grounded in the physiological interplay between cardiac and pulmonary systems. These metrics are extracted from circulatory oscillations induced by shifts in intrathoracic pressure during volume-controlled mechanical ventilation. Evidence supports their utility in forecasting fluid responsiveness in patients under mechanical ventilation [8].
More recently, the ratio of PPV (pressure-derived) to SVV (flow-derived) has been introduced as a surrogate marker for dynamic arterial elastance (Eadyn). This parameter offers a means to distinguish between hypotension caused by arterial vasodilation and that due to hypovolemia. Eadyn may also serve as a predictor of vascular tone modulation following fluid administration, particularly in relation to norepinephrine requirements [9].
Personalized goal-directed hemodynamic therapy (GDHT) involves tailoring the administration of fluids, inotropes, and vasopressors based on continuous monitoring of cardiac output and other hemodynamic variables. Its primary objective is to minimize perioperative complications, potentially lowering both morbidity and mortality rates [10].
A substantial body of research has demonstrated that perioperative GDHT can enhance clinical outcomes, especially in patients undergoing abdominal procedures [11,12], as well as in trauma and orthopedic surgeries [13]. Moreover, GDHT protocols incorporating PPV have shown promising results in improving patient prognosis [14].
The aim of the current study of patients undergoing major hepatic resection was comparing standard perioperative (control Group) to hemodynamic management based on PPV, SVV, continuous CO trending and dynamic arterial elastance using radial artery pulse contour analysis (GDHT group). We hypothesize that the personalized use of this treatment regimen following liver resection leads to a reduction in the total volume infused and in intraoperative transfusion (primary endpoint) and reduced postoperative complications and length of hospital stay (secondary endpoint).
2. Materials and Methods
2.1. Study Design and Protocol
This prospective, randomized clinical trial was conducted at the Departments of Anesthesiology and Intensive Care Medicine and Surgery of the University General Hospital of Ciudad Real, Spain. The study received approval from the institutional ethics committee (protocol code RD223/04. Date of approval: 25 November 2014, Acta 1/2014) and was registered at ClinicalTrials.gov (NCT04517409). Patients scheduled for hepatic resection involving more than two liver segments were considered eligible. The primary indications for hepatic resection in our study were colorectal liver metastases and hepatocellular carcinoma. Exclusion criteria included: age under 18 years, body weight below 50 kg or above 150 kg, irregular cardiac rhythm, severe cardiovascular disease (e.g., chronic heart failure, valvular pathology, cardiomyopathy), and advanced liver dysfunction (Child-Pugh class B or C). Written informed consent was obtained from all participants prior to enrollment.
2.2. Randomization and Group Allocation
Eligible patients were randomly assigned in a 1:1 ratio to one of two groups: (1) standard perioperative care (Control group), or (2) goal-directed hemodynamic therapy (GDHT group) guided by radial artery pulse contour analysis. Randomization was performed the day before surgery by the lead investigator responsible for anesthesia, using sealed opaque envelopes stored in non-transparent containers. Only patients were blinded to group allocation; blinding of care providers and investigators was not feasible due to the use of cardiac index monitoring devices.
2.3. Intraoperative Management
All patients received balanced general anesthesia with intravenous induction and neuromuscular blockade, administered at the discretion of the attending anesthesiologist. Depth of anesthesia was monitored using bispectral index (BIS), with maintenance via sevoflurane targeting a BIS range of 40–60. Central venous catheterization and invasive radial arterial pressure monitoring were performed based on anesthesiologist preference.
Standard monitoring included five-lead electrocardiography, pulse oximetry, and non-invasive blood pressure measurement. At least one peripheral intravenous line was established. Intraoperative goals included maintaining oxygen saturation >94%, normothermia, and heart rate <100 beats per minute. Mechanical ventilation with an inspired oxygen fraction of 60% was used to maintain arterial carbon dioxide tension (PaCO_2_) between 4.7 and 6.0 kPa, with a positive end-expiratory pressure (PEEP) of 4–6 mmHg and tidal volumes of 6–8 mL/kg.
Ephedrine was administered in cases of hemodynamic instability (mean arterial pressure < 65 mmHg). If repeated boluses were ineffective, norepinephrine infusion was initiated. In the event of acute blood loss (>150 mL/min or >500 mL), colloid solutions (Gelaspan^®^ 40/mg) were administered within the recommended maximum dose (30 mL/kg).
In both groups, blood loss was compensated with colloid infusion at a 1:1 ratio. Packed red blood cells were transfused when hemoglobin levels fell below 10 g/dL in patients with cardiac comorbidities, or below 7 g/dL in those without.
Hemodynamic parameters were recorded every 15 min. Arterial and central venous blood gas analyses were performed at the beginning, midpoint, and end of hepatic resection. At the conclusion of surgery, total catecholamine usage, estimated blood loss, urine output, and fluid administration were documented. The time from surgery completion to extubation was also recorded.
2.4. GDHT Group
In the GDHT group, the arterial catheter was additionally connected to a cardiac index trending monitor (ProAQT™, PULSION Medical Systems SE, Munich, Germany).
Fluid management followed a predefined protocol (Figure 1). During the static phase (prior to hepatic resection), all patients received a continuous infusion of balanced crystalloid solution (Ringer’s lactate) at a rate of 1 mL·kg^−1^·h^−1^.
Following hepatic resection, the dynamic phase commenced with an initial hemodynamic assessment based on pulse pressure variation (PPV), cardiac index (CI), and mean arterial pressure (MAP), as outlined in Figure 1. Preload optimization was achieved by administering 4 mL·kg^−1^ boluses of colloid solution every 5 min until PPV was <14% or stroke volume variation (SVV) was <12%. At this point, the patient’s individualized, preload-optimized CI was established and used as the target hemodynamic parameter for the remainder of the procedure.
If the optimized CI was below 2.5 L·min^−1^·m^−2^, inotropic support was initiated to reach this minimum threshold, serving as a safety measure to prevent low cardiac output. If PPV and CI were within target ranges but MAP remained <65 mmHg or the PPV/SVV ratio exceeded 1.2, vasopressor therapy was started.
After the initial assessment, patients were re-evaluated every 15 min throughout the intraoperative period to ensure maintenance of hemodynamic parameters in accordance with the study algorithm (Figure 1).
2.5. Control Group
During the static phase (prior to hepatic resection), patients in the control group received a continuous infusion of balanced crystalloid solution with the goal of maintaining a central venous pressure (CVP) of approximately 5 mmHg.
In the dynamic phase (after hepatic resection), fluid therapy—including colloid administration—as well as vasopressor and inotropic support were provided at the discretion of the attending anesthesiologist, based on CVP, MAP, and urine output. Cardiac output monitoring was not performed in this group. Intraoperative management goals were intentionally flexible to avoid extremes of clinical practice and to reflect real-world variability.
2.6. Postoperative Management
All patients were monitored in the post-anesthesia care unit (PACU) prior to transfer to the surgical ward. Arterial and central venous blood gas analyses were performed immediately before PACU discharge, and the duration of PACU stay was recorded in minutes.
Twenty-four hours after surgery, data were collected on catecholamine use, estimated blood loss, urine output, and total fluid administration. Postoperative complications and length of hospital stay were documented. Complications were predefined in the study protocol and categorized as follows: Infectious (respiratory, abdominal, urinary tract, or surgical site infections), Respiratory (mechanical ventilation > 24 h, failed extubation), Cardiovascular (atrial fibrillation, acute myocardial infarction, ventricular fibrillation, pulmonary edema, hypotension (MAP < 50 mmHg), stroke), Abdominal (reoperation, gastrointestinal bleeding, hepatic dysfunction), Renal (acute kidney injury), Other (wound dehiscence, deep vein thrombosis).
2.7. Endpoints
2.7.1. Primary Endpoint
The primary endpoint was the volume of fluid administered intraoperatively and postoperatively, as well as the number of blood transfusions.
2.7.2. Secondary Endpoints
Secondary endpoints included intraoperative laboratory parameters, use of vasopressors, duration of hepatic resection, and total surgical time. Postoperative complications were recorded based on patient chart review and direct ward visits by investigators. Definitions of complications were updated to align with current standards [15].
Additional outcomes included length of hospital stay (in days), duration of intensive care unit stay, and all-cause postoperative mortality. Baseline data collected included sociodemographic characteristics, ASA physical status classification [16], comorbidities, and preoperative hemoglobin levels.
2.8. Statistical Analysis
Quantitative variables are presented as mean ± standard error of the mean (SEM) and visualized using box plots. Group comparisons (Control vs. GDHT) were performed using Student’s t-test or the Mann–Whitney U test, depending on the normality of data distribution.
For within-group comparisons of hemodynamic changes in the GDHT group, paired Student’s t-tests or Wilcoxon signed-rank tests were used, based on normality assessment. A p-value < 0.05 was considered statistically significant, with a 95% confidence interval (CI). Statistical analyses were conducted using SPSS version 24.0 (IBM Corp., New York, NY, USA).
3. Results
The study was performed for two years. In this period, 45 patients were scheduled for open large liver resection (two or more liver segments). No patient was excluded or dropped out of the study after randomization (N = 35). There were 16 patients in the control group and 19 patients in the GDHT group (Figure 2).
There were no significant differences between the groups regarding to demographics, baseline laboratory parameters and surgical characteristics (Table 1).
3.1. Intra- and Postoperative Laboratory Parameters
There was no significant difference in Laboratory parameters before, after resection hepatic and third postoperative day (Table 2).
3.2. Fluids and Catecholamines
3.2.1. Fluid Management
Blood loss was significantly higher in the control group than in GDHT group (728.13 ± 618.59 versus 292.63 ± 274.06, p = 0.009). The number of patients receiving intraoperative transfusion was significantly higher in the first group (6 ± 16 versus 0 ± 19, p = 0.005). However, in the postoperative (Intensive Unit) transfusion there was no significant differences (Table 3).
Total volume infused was significantly higher in control group (CG) than in GDHT group (GG) (2853.13 ± 1432.18 versus 1125.79 ± 751.2, p = 0.001), although more marked in static phase (1403.13 ± 1146.51 versus 276.32 ± 189.56, p = 0.001). Also, urine output was significantly higher in control group than in GDHT group (430.63 ± 310.26 versus 206.84 ± 133.2, p = 0.007) (Table 3).
3.2.2. Vasopressor
As listed in Table 3, the number of patients receiving intraoperative vasopressor was equal in the two groups (CG:6 ± 16 versus GG:6 ± 19, p = 0.495). Few patients required vasopressors postoperatively with no significant difference between the two groups (CG:6 ± 16 versus GG:4 ± 19, p = 0.311)
3.3. Complications and Outcome
The overall number of complications was similar between the two groups (CG: 8 ± 16 versus GG: 7 ± 18, p = 0.38) with no significant difference. Further, there were no significant differences in the duration of stay in the intensive care unit (CG: 10.69 ± 9.01 versus GG: 10.05 ± 3.8, p = 0.783) or length hospital stay (CG: 4.19 ± 4.07 versus GG: 3.42 ± 1.9, p = 0.471) in the two groups (Table 3).
The number of patients who died at 180 days of follow-up in CG was higher than in GG (2 ± 16 versus 0 ± 19, p =0.171) but with no statistically significant difference. In the same day, the number of patients attending to the global mortality in CG was higher than in GG (5 ± 16 versus 4 ± 19, p = 0.381) but no statistically significant difference (Table 3).
3.4. Hemodynamic Changes in the GDHT Group
After hepatic resection and hemodynamic optimization according to protocol (Figure 1), there were statistically significant changes in VPP (T2: 19.37 ± 7.96 versus T3: 8.47 ± 1.5, p = 0.001), VVS (T2: 19.84 ± 7.05 versus T3: 9.95 ± 1.31, p = 0.001) and HR (82.26 ± 18.19 versus 20.53 ± 14.02, p = 0.001). In all other variables (CI, SVR, MAP) and times (T2-T1 and T3-T2) there are no statistically significant changes (Table 4 and Figure 3).
4. Discussion
Haemodynamic optimization protocols aim to optimize preload and improve cardiac output and tissue perfusion [17]. Personalized haemodynamic optimization includes goal-directed haemodynamic therapy (GDHT). The main aim is to administer the fluid that benefits the patient by avoiding fluid overload, since this results to worse clinical outcomes and increase morbidity and mortality [18,19].
The data from this study is to demonstrate how GDHT is able to administer less fluid to the patient during the dynamic phase after hepatic resection. In addition, the proposed restrictive therapy versus liberal therapy guided by CVP allows less fluid administration during the static phase leading to less surgical time and less bleeding during liver resection. It is therefore one of the first randomized studies in hepatic resection that show how GDHT leads to decreased fluid administration and less intraoperative blood transfusion by using the variables SVV and PPV derived from the radial artery pulse contour.
Other clinical trials of GDHT had also used, as in our study, colloid solutions for intraoperative medical management and ensure an optimized cardiac output, without renal failure [20]. Intraoperative diuresis was significantly lower in the GDHT group, although no increased rate of renal dysfunction was found in the postoperative period. We did not find differences in creatinine and urea parameters (Table 2) in the postoperative period.
In our study, the GDHT group received a restrictive therapy until the end of the hepatic resection which leaded to increased values of the variables PPV, SVV, and CI that showed the expected good response to volume administration. After the administration of the colloid solution, these values were normalized and the heart rate decreased. Therefore, these dynamic parameters would be a better predictor of volume administration than the classic CVP and PAOP that could be altered by the manipulation of the abdominal cavity, the use of vasoconstrictors, mechanical ventilation, etc., and do not correlate with changes in CI after volume expansion [21]. In this way, there are studies that have reported that the CVP can be used as a guide to fluids in hepatic surgery [22], but as it is stated in our study, the patients assigned to the control group received much more volume and blood transfusion.
Several authors have reported that indicate that slight pulmonary edema may occur after liver resection, so patients may benefit from the fluid restriction therapy that we performed in the GDHT group [23]. Some authors have indicated that measuring CVP is not essential to improve hemodynamic control during liver resection [24].
Detailed analysis of intraoperative parameters suggests that, in the GDHT group, volume expansion was required following hepatic resection to achieve optimal values for SVV, PPV, CI, and MAP. We propose that the structured algorithm used in this study facilitated timely fluid administration without hesitation due to concerns about volume overload [25]. The intervention—modification of hemodynamic therapy—was initiated intraoperatively, with the rationale of implementing early goal-directed therapy to maximize its benefits throughout the perioperative period.
Our findings revealed a significant reduction in systemic vascular resistance (SVR) and a concomitant increase in cardiac index (CI) after hepatectomy. These hemodynamic changes are consistent with those reported by Bharathy et al. [26], and may be attributed to the release of splanchnic mediators such as nitric oxide, endotoxins, and pro-inflammatory cytokines [27].
Pearse et al. [28] demonstrated a reduction in postoperative complications following GDHT, attributed to enhanced global oxygen delivery via volume optimization and inotropic support. Their hypothesis was that improved tissue oxygenation promotes healing and reduces infection rates. Although we did not directly measure tissue oxygen demand or partial pressure of oxygen, our algorithm aimed to optimize intravascular volume and CI, likely contributing to improved tissue perfusion and oxygenation.
In our study, the GDHT group exhibited fewer postoperative complications, shorter hospital stays, and lower mortality rates, although these differences did not reach statistical significance. Larger studies in different surgical populations have demonstrated significant benefits of GDHT [29].
Importantly, the monitoring system used in our study was minimally invasive, requiring only a single arterial line. This feature enhances its applicability across a wide range of surgical procedures [23].
Our study had some limitations such as the reduced number of patients, since it is a study of major hepatic surgery and therefore we could not establish a statistically significant difference in the primary endpoint. The anesthesiologists, surgeons and nurses could not be blinded due to the need to use the proAQT device. Furthermore, the parameters of SVV, PPV and CI in the control group were not monitored in order not to interfere with hemodynamic management, although such practice would have been of interest later on compared to the GDHT group. The proposed algorithm could not be established as superior to others used previously and new trials would be needed in the future [30]. Both groups were treated by anesthesiologists with extensive clinical experience. During the static phase in the control group, a liberal fluid administration strategy was employed, reflecting the standard perioperative practice at our institution at the time of the study. Although Eadyn was monitored intraoperatively, it was not systematically recorded for all patients and therefore could not be included in the final analysis.
The results of this study would not be transferable to all patients undergoing liver resection since pulse wave analysis only works reliably in patients without severe arrhythmias and controlled mechanical ventilation.
Finally, the limited sample size and the single-center design restrict the generalizability of our findings. Therefore, this study should be considered exploratory, and we hope it will serve as a foundation for future multicenter trials with greater statistical power.
Personalized, goal-directed therapy optimizes intraoperative fluid administration during major liver resection and reduces surgical times and blood transfusions. We observed fewer complications, hospital stays and mortality at 180 days, but without statistical significance.
Continuous arterial pressure monitoring during major hepatic resection facilitates the use of pulse contour analysis systems, thereby enabling a more rational and individualized approach to perioperative fluid management in patients undergoing hepatectomy. Further prospective studies are warranted to evaluate the impact of personalized goal-directed therapy on perioperative outcomes in this population. Whenever feasible, the implementation of minimally invasive monitoring technologies should be prioritized, as they may contribute to improved quality of care and reductions in postoperative morbidity and mortality.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Abdelmalak J. Strasser S.I. Ngu N. Dennis C. Sinclair M. Majumdar A. Collins K. Bateman K. Dev A. Abasszade J.H. Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study Cancers 202315574110.3390/cancers 1524574138136287 PMC 10742146 · doi ↗ · pubmed ↗
- 2Ferrero A. Russolillo N. ViganòL. Lo Tesoriere R. Muratore A. Capussotti L. Does Pringle maneuver affect survival in patients with colorectal liver metastases?World J. Surg.2010342418242510.1007/s 00268-010-0682-220559637 · doi ↗ · pubmed ↗
- 3Liu T.S. Shen Q.H. Zhou X.Y. Shen X. Lai L. Hou X.M. Liu K. Application of controlled low central venous pressure during hepatectomy: A systematic review and meta-analysis J. Clin. Anesth 20217511046710.1016/j.jclinane.2021.11046734343737 · doi ↗ · pubmed ↗
- 4Messina A. Grieco D.L. Alicino V. Cecconi M. Teboul J.L. Monnet X. Assessing fluid responsiveness by using functional hemodynamic tests in critically ill patients: A narrative review and a profile-based clinical guide J. Clin. Monit. Comput.20253948149310.1007/s 10877-024-01255-x 39831948 · doi ↗ · pubmed ↗
- 5Kim J.H. Should low central venous pressure be maintained during liver transplantation?Open Anesthesiol. J.201711172410.2174/1874321801711010017 · doi ↗
- 6Niemann C.U. Feiner J. Behrends M. Eilers H. Ascher N.L. Roberts J.P. Central venous pressure monitoring during living right donor hepatectomy Liver Transplant.20071326627110.1002/lt.2105117256757 · doi ↗ · pubmed ↗
- 7Vos J.J. Kalmar A.F. Struys M.M.R.F. Wietasch J.K.G. Hendriks H.G.D. Scheeren T.W.L. Comparison of arterial pressure and plethysmographic waveform-based dynamic preload variables in assessing fluid responsiveness and dynamic arterial tone in patients undergoing major hepatic resection Br. J. Anaesth.201311094094610.1093/bja/aes 50823348202 · doi ↗ · pubmed ↗
- 8Monnet X. Shi R. Teboul J.L. Prediction of fluid responsiveness. What’s new?Ann. Intensive Care 2022124610.1186/s 13613-022-01022-835633423 PMC 9148319 · doi ↗ · pubmed ↗
